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Abstract 
To study the assembly of mitochondtial F,Fn ATP synthase, cultured human cells were labeled with [35S]methionine in pulse-chase 
experiments. Next, two-dimensional electrophoresis and fluorography were used to analyze the assembly pattern. Two assembly 
intermediates could be demonstrated. First the F, part appeared to be assembled, and next an intermediate product that contained F, and 
subunit c. This product probably also contained subunits b, F6 and OSCP, but not the mitochondrially encoded subunits a and A6L. Both 
intermediate complexes accumulated when mitochondrial protein synthesis was inhibited, suggesting that mitochondrially encoded 
subunits are indispensable for the formation of a fully assembled ATP synthase complex, but not for the formation of the intermediate 
complexes. The results and methods described in this study offer an approach to study the effects of mutations in subunits of 
mitochondrial ATP synthase on the assembly of this complex. This might be of value for a better understanding of deficiencies of ATP 
synthase activity in mitochondrial diseases. 
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1. Introduction 
Mitochondrial ATP synthase (F,F,, ATPase, or complex 
V) catalyses the synthesis of ATP from ADP and Pi at the 
expense of the proton gradient across the mitochondrial 
innermembrane. It is a multisubunit complex consisting of 
two functional domains, F, and F, [1,2]. The F, part is a 
hydrophilic part which contains five distinct subunits (3 (Y, 
3p, y, u and E) [3]. The F,, domain is the hydrophobic 
part which is embedded in the mitochondrial inner mem- 
brane and contains the subunits a,b,c,d,e,f,g and A6L [4,5]. 
F0 functions as a proton pore and directs the energy 
released by the proton flux to the catalytic sites of F, 
[6-81. The F, part is located in the matrix and is connected 
to the F, part by a stalk that contains the subunits OSCP, 
F6, b and d [8]. 
Abbreviations: FCS, fetal calf serum; PBS, phosphate-buffered saline; 
TCA, trichloroacetic acid; SDS, sodium dodecyl sulfate; PAGE, poly- 
acrylamide gel electrophoresis. 
* Corresponding author. Fax: + 31 20 6915519. 
Subunits a and A6L are encoded by the mitochondrial 
genome [9], whereas the other subunits of the enzyme are 
encoded by nuclear genes. ATP synthase deficiency can 
therefore be due to mutations of either nuclear or mito- 
chondrial genes. So far, only one case has been described 
in which ATP synthase deficiency is most likely caused by 
a mutation in one of the nuclearly encoded subunits of the 
enzyme [lo]. Mutations in the mitochondrial genome that 
might affect the activity of ATP synthase are more fre- 
quently observed [l l-171. For instance, point mutations in 
the ATPase 6 gene, encoding subunit a, are well known 
[ 13-171. In addition, impairment of mitochondrial gene 
expression due to either partial deletions, to depletion of 
mitochondrial DNA, or to point mutations in mitochondrial 
tRNA genes [ 1 l-131, can also decrease the synthesis of 
mitochondrially encoded subunits of the ATP synthase 
complex. Cultured cells treated with doxycycline, a spe- 
cific inhibitor of mitochondrial protein synthesis, may 
serve as a model to study the effects of impaired synthesis 
of mitochondrially encoded subunits on the assembly or 
stability of enzymes that contain subunits of both mito- 
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chondrial and nuclear origin such as the ATP synthase 
complex [ 181. 
So far, no in vivo studies of the assembly of mitochon- 
drial ATP synthase have been performed in higher eukary- 
otes. In the present study, we followed the assembly 
pathway of the ATP synthase complex in human cells, 
cultured in the absence or the presence of doxycycline. 
The results indicate that F, is assembled first, whereafter a 
subcomplex is formed in which F, is associated with at 
least subunit c, and most probably also with subunits b, 
OSCP and F6. In the following step the remaining subunits 
are assembled, which completes the formation of the ATP 
synthase complex. When mitochondrial protein synthesis is 
inhibited, the first two assembly steps still occur, but 
assembly of the complete complex is hampered, resulting 
in decreased steady-state levels of ATP synthase. 
2. Materials and methods 
2.1. Cell cultures 
The human leukemia cell line Molt-4 (growing as a 
suspension culture) was cultured in Dulbecco’s modified 
Eagle medium containing 1 mM pyruvate and supple- 
mented with 10% heat-inactivated fetal calf serum (FCS), 
at 37°C in a humidified atmosphere of 10% CO, in air 
[ 19,201. Doxycycline, a specific inhibitor of mitochondrial 
protein synthesis, was added to a final concentration of 15 
pg per ml of culture medium as described before [21]. 
2.2. Metabolic labeling 
Control cells or doxycycline-treated cells from exponen- 
tially growing cultures were collected by centrifugation 
and washed twice with phosphate-buffered saline (PBS). 
The pellet was resuspended in methionine-free Dulbecco’s 
modified Eagle medium containing 1 mM pyruvate and 
supplemented with 10% FCS. Doxycycline (15 pg/ml) 
was added to cell cultures that had been grown before in 
the presence of doxycycline. The cell concentration was 
determined using a counting chamber. After 1 h of cultur- 
ing in a humidified atmosphere of 10% CO, in air, 
[ 35S]methionine (spec. act. > 960 Ci/mmol) was added to 
a final concentration of 20 &i per ml, at a cell density of 
1 X lo6 cells/ml. At various time points, 10 X lo6 cells 
were collected by centrifugation and resuspended in Dul- 
becco’s modified Eagle medium containing unlabeled me- 
tbionine, I mM pyruvate and 10% FCS. The cells were 
washed twice with PBS and processed further for two-di- 
mensional electrophoresis (2-D electrophoresis) as de- 
scribed below. A small aliquot of the samples prepared for 
2-D electrophoresis was used to measure the total incorpo- 
ration of radioactivity in the mitochondrial fraction as 
trichloroacetic acid-precipitable counts. 2-D gels were dried 
under vacuum and labeled proteins were visualized by 
fluorography [22]. The autoradiographic signals of proteins 
were quantified on gels using a PhosphorImager’” (Molec- 
ular Dynamics, USA). 
2.3. Two-dimensional electrophoresis 
Two-dimensional electrophoresis was performed using 
a modification (P. Klement et al., unpublished results) of 
the method described by Schlgger and Von Jagow 1231. 
This method allows analysis-of both the concentration and 
composition of (mitochondrial) enzyme complexes, using 
mitoplasts obtained by digitonin treatment of cultured cells 
as starting material. 10 X lo6 cells were harvested by 
centrifugation, washed twice with cold PBS and resus- 
pended in 100 )(~l PBS, whereafter the same volume of 
digitonin (4 mg/ml) was added. The samples were incu- 
bated for 15 min on ice, diluted 7 times with PBS, and 
centrifuged at 10 000 X g. The pellets were washed once 
with PBS and then used as starting material for 2-D 
electrophoresis. In the first dimension, separation of the 
complexes under native conditions occurs according to 
molecular mass, and in the second dimension, where elec- 
trophoresis is performed under denaturing conditions, the 
individual subunits of the complexes are resolved. The gels 
were stained either with silver [24] or used for immuno- 
blotting as described before [ 17,181. Immunoreactive mate- 
rial was visualized by chemiluminescence (ECL’“, Amer- 
sham, UK) according to the instructions of the manufac- 
turer. 
2.4. N-terminal amino acid sequencing 
Two-dimensional electrophoresis was performed as de- 
scribed above. The proteins were transferred by elec- 
troblotting from the gels to PVDF membranes (Bio-Rad, 
USA). The membranes were stained with Coomassie bril- 
liant blue R250 and the spots of interest were cut out. The 
N-terminal amino acid sequence of these proteins was 
determined on a 477 A pulsed-liquid sequencer (Applied 
Biosystems, USA). 
3. Results 
3.1. Steady-state concentration of mitochondrial enzyme 
complexes 
The content and composition of mitochondrial enzyme 
complexes was analyzed in control cells and compared to 
that of cells in which mitochondrial protein synthesis had 
been inhibited by treatment with doxycycline for two or 
four days. Fig. 1A shows the mitochondrial enzyme com- 
plexes from control Molt-4 cells, as visualized after 2-D 
electrophoresis and silver staining. The complexes II, III, 
IV and V could be identified because of their mobility in 
the first dimension and the characteristic pattern of the 
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Fig. 1. Composition and steady-state concentration of mitochondrial enzyme complexes in control cells and cells treated with doxycycline. Mitochondria 
from control Molt-4 cells (A) and cells cultured for 2 (B) or 4 days (Cl in the presence of doxycycline, were used as starting material for 2-D 
electrophoresis. The amount of starting material of doxycycline-treated cells was raised such that the expected content of complex V was about the same as 
in control cells. The gels were stained by silver. II, III, IV, V: complexes II, III, IV and V. H: complexes containing HSP60. The rectangles are enlarged at 
the right. V * and F,: intermediate complex V * (see Section 3) and F,-ATPase. On the left of the enlarged part of the gel, the position of the (Y and p 
subunits of the ATP synthase and that of HSP60 are indicated. 
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Fig. 2. Western blot analysis of subcomplexes of ATP synthase in doxycycline-treated cells. The enzyme complexes from mitochondria of control cells (A) 
and cells treated for 2 days with doxycycline (B) were separated in the first dimension by blue-native PAGE (Al, Bl) and in the second dimension by 
SDS-PAGE (A2, B2) as described in Section 2, and next blotted. For an easy comparison of first and second dimension gels, B 1 is also shown below the 
picture of the blot of the second dimension gel, where it is indicated as B 1 * The blot from the first dimension and the upper part of the blot from the 
second dimension gel were incubated with an antibody against F,-ATPase (A2a, B2a) and the lower part of the blot was incubated with an antibody against 
subunit c (A2b, B2b). V, V * and F,: complex V, intermediate complex V * (see Section 3) and F,-ATPase. a, p, y and c: subunits (Y, p, y and c of 
complex V. 
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subunits in the second dimension [ 18,231. However, com- 
plex I was not clearly visible, possibly because of a low 
steady-state concentration of complex I in this cell type. In 
addition, two rather identical complexes composed of sev- 
eral peptides were found (indicated by H). N-terminal 
amino acid sequencing of the first 10 amino acids identi- 
fied the most upper spots of these complexes as HSP60. 
The apparent molecular weights of these complexes were 
approx. 380 kDa and 450 kD,a respectively. The 380 kDa 
spot and the 450 kDa spot might therefore represent 
multimers of HSP60 [25]. The nature of these HSP60-con- 
taining complexes is currently under investigation. 
Except for complex II, cells treated with doxycycline 
showed a decrease of the content of respiratory chain 
complexes, as was demonstrated before [ 181. Also complex 
V, or ATP synthase (apparent molecular weight around 
630 kDa), showed a significantly reduced concentration. 
Furthermore, a relative increase in content of a number of 
other protein complexes was seen, which became more 
evident as doxycycline treatment had lasted longer. These 
complexes and their possible relationship with oxidative 
phosphorylation enzymes were investigated in detail. To 
this end, the amount of starting material for 2-D elec- 
trophoresis from cells that had been cultured in the pres- 
ence of doxycycline was raised such that the content of 
complex V was expected to be the same as that in control 
cells (Figs. 1 and 2). One of the complexes that showed an 
elevated content in doxycycline-treated cells, had a molec- 
ular weight of f 390 kDa (F,, see below) and contained 
polypeptides with molecular weights that were identical to 
that of the LX and p subunits of the ATP synthase com- 
plex. Another complex with a molecular weight of about 
460 kDa (V *, see below) also contained these poly- 
peptides (Fig. 1 A,B,C). Further analysis of these com- 
plexes by Western blotting of the first dimension gels (Fig. 
2A1,B 1) revealed that both complexes (and complex V) 
V Fl 
V V*Fl 
Fig. 3. Synthesis and stability of ATF’ synthase subcomplexes in doxycycline-treated cells. Control Molt-4 cells (A) and cells treated for two days with 
doxycycline (B) were pulse labeled with [35S]methionine for 1 h and chased for 6 h. Detection was performed by fluorography. The right panel shows the 
relevant part of the gel in enlarged form. II, III, IV, V, H, V * , F,, o and p, see legends to Figs. 1 and 2. 
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reacted with an antibody raised against the F, part of ATP 
synthase. Analysis of second dimension gels by Western 
blotting using an antibody directed against F,-ATPase, 
revealed that all these complexes contained at least the (Y, 
p and y subunits of F, ATPase (Fig. 2A2a,B2a). Incuba- 
tion of the lower part of the blot with an antibody raised 
against subunit c of the F,, part of ATP synthase (Fig. 
2A2b,B2b) showed that only the 630 kDa and the 460 kDa 
complexes reacted with this antibody. The molecular 
weights and subunit composition confirmed therefore that 
the 630 kDa complex represented fully assembled complex 
V, and suggested that the 390 kDa complex was identical 
to the F, part of complex V, whereas the 460 kDa complex 
might represent an intermediate form. Western blot analy- 
sis also revealed the presence of unassembled subunits cy, 
p and y in both control cells and doxycycline treated 
cells. Apparently, there is a pool of these (and possibly 
also of other subunits of ATP synthase) subunits in cul- 
tured cells. On the blot of doxycycline-treated cells also a 
immunoreactive spot to subunit c was observed close to 
the front of the first dimension (Fig. 2B2b), which was not 
the case for control cells. Possibly, this spot is part of 
another subcomplex of F, or represents a multimer of 
subunit c. 
3.2. Synthesis and stability of ATP synthase subcomplexes 
In order to study the assembly and stability of both 
subcomplexes of the ATP synthase that were identified 
above, pulse-chase experiments were performed with con- 
trol cells and cells treated for two days with doxycycline. 
Fig. 3 shows two typical gels of control cells (Fig. 3A) and 
of cells treated with doxycycline (Fig. 3B). Complexes III, 
IV and V, as well as the F, part of the ATP synthase and 
HSP60 complexes were visible after labeling of control 
cells. In doxycycline-treated cells no labeled complex III 
or IV could be observed and there was a decreased amount 
of fully assembled, labeled complex V. However, approxi- 
mately equal amounts of HSP60 complexes were found 
and increased amounts of both F,-ATPase (390 kDa) and 
the ATP synthase subcomplex of 460 kDa (V * >. 
Since the LY and p subunits were not only part of 
complex V, but also of subcomplex V * and the F,-ATPase 
(see above), the intensity of these subunits could be used 
as a measure for the amount of the respective (sub)com- 
plexes. Fig. 4 displays the amount of labeled (sub)com- 
plexes of ATP synthase that were assembled after an 1 h 
pulse, followed by a chase of 0, 1, 2, 4, 6 and 24 h. The 
amount of complex V (Fig. 4a) in control cells increased 
rapidly up to a chase period of 6 h and remained almost 
constant for 24 h. In contrast, in doxycycline-treated cells 
only a slight increase of assembled complex V was seen 
during a chase of 6 h. After a chase period of 24 h, the 
total amount of newly assembled complex V was only 
20% of that in control cells. The assembly pattern of 
F, -ATPase (Fig. 4b) showed an opposite picture. In control 
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Fig. 4. Rate of assembly of ATP synthase subcomplexes. The amount of 
complexes of ATP synthase as shown in Fig. 3 was quantified by 
Phosphorlmager analysis, using the signals of the LY and p subunits 
incorporated in complex V (a), F,-ATPase (b) and intermediate complex 
V * (c). The amount obtained was corrected for the amount of TCA-pre- 
cipitable counts incorporated in the mitochondrial fraction used for 
electrophoresis. 0, control cells; A, doxycycline-treated cells. 
cells the amount of F,-ATPase remained constant during a 
chase of 24 h, but in doxycycline-treated cells the amount 
of newly formed F, increased up to a chase of 6 h. Even 
after a chase of 24 h, 5 times more F,-ATPase was still 
present in comparison to control cells. The most obvious 
explanation for this observation is that control cells, in 
contrast to doxycycline-treated cells, use the F,-ATPase to 
assemble complex V. The more or less constant levels of 
labeled F,-ATPase during the chase in control cells might 
be due to turnover of newly assembled complex V. Alter- 
natively, F,-ATPase is constantly supplied by formation 
from the pool of unassembled subunits (see Fig. 2). How- 
ever, the amount of labeled F,-ATPase in control cells was 
only minor in comparison to that of complex V. In cells 
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treated with doxycycline, far less assembled ATP synthase 
was formed than in control cells. It is, thus, unlikely that 
the extensive accumulation of labeled F,-ATPase in doxy- 
cycline-treated cells is mainly the result of degradation of 
newly formed ATP synthase. As the rate of synthesis of 
nuclearly encoded subunits of mitochondrial enzyme com- 
plexes is not influenced by treatment with doxycycline 
[ 181, the most probable explanation is therefore that the 
F,-ATPase is constantly being assembled from the pool of 
newly synthesized subunits, but hardly used for the assem- 
bly of ATP synthase, and thus accumulates in 
doxycycline-treated cells. 
The assembly of complex V * (Fig. 4c) resembled the 
assembly of F,-ATPase. In control cells chased for 2 h 
complex V * was not detectable anymore, whereas in 
doxycycline-treated cells the amount of newly formed 
complex V * increased during a chase of 4-6 h, and 
remained constant thereafter. As is the case for the F, 
complex, control cells most probably use the complex V * 
in the assembly of ATP synthase, while in doxycycline- 
treated cells complex V * accumulates because of impaired 
assembly of complex V. The accumulation of complex V * 
in doxycycline-treated cells did not increase further than 
10% of the amount of F, ATPase. Accumulation of com- 
plex V * might be limited because of instability of this 
complex. This is in line with the appearance of the subunit 
c containing subcomplex close to the front of the first 
dimension gels on Western blots of doxycycline-treated 
cells (Fig. 2B2b). The disappearance of complex V * dur- 
ing chasing clearly indicates that also complex V * is a 
true assembly intermediate and not a degradation product. 
These results fully explain the reduction of the steady-state 
concentration of ATP synthase and the accumulation of 
F,-ATPase and complex V * in doxycycline-treated cells. 
4. Discussion 
The results of the present study partly reveal the assem- 
bly pathway of ATP synthase in cultured human cells. The 
use of pulse-chase labeling, in combination with 2-D elec- 
trophoresis had the large advantage that the results were 
not dependent on the specificity and properties of antibod- 
ies, the use of which may result in selective loss of one ore 
more subunits during immunoprecipitation. Moreover, 
these experimental approaches allowed analysis of the 
assembly pattern of complex V under in vivo conditions, 
studies which have so far not been performed in higher 
eukaryotes. 
It can be concluded from our results that the assembly 
of ATP synthase in human cells occurs via minimally two 
assembly intermediates. First a complex is assembled of 
around 390 kDa in which at least subunits (Y, /3, and y are 
present, but not subunit c. Because of its apparent molecu- 
lar weight and subunit composition, it is highly likely that 
this complex represents the F, part of ATP synthase. The 
synthesis of F, is not influenced by inhibition of mitochon- 
drial protein synthesis, which is in line with both the 
accumulation of the steady-state concentration of F, and 
the results of SDS-PAGE followed by Western blotting 
that we described before [18]. A second complex (V * > 
contains at least the (Y, p and y subunits of F, and subunit 
c of the Fo part. This complex disappeared during a chase 
in control cells, and is therefore most probably also an 
assembly intermediate. Since not only the F, part, but also 
the subunits OSCP, F6, and b are required for the connec- 
tion of F, to F, in the bovine ATP synthase complex [26], 
these subunits are also likely to be present in complex V * 
Complex V * accumulates when the synthesis of the mito- 
chondrially encoded subunits (a and A6L) is impaired, 
Fl -ATPase 
I I 
intermediate 
complex V 
inner 
membrane 
Fig. 5. Model for the assembly pathway of ATP synthase in human cells and the influence of impaired mitochondrial protein synthasis. First F, -ATPase is 
assembled. Next subunits OSCP, b, F6, c and probably some other subunits (e.g., subunit d) are assembled to form the intermediate complex V * Subunit 
a, and A6L and other subunits (e.g., subunits e, f and g) are assembled to complete complex V. When mitochondrial protein synthesis is impaired, the final 
assembly step does not take place and the assembly intermediates F,-ATPase and complex V * accumulate. 
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suggesting that the mitochondrial subunits are not part of 
it. In doxycycline-treated cells, assembly of complex V 
was still observed, but at a much lower level than in 
control cells. This implies that after two days of inhibition 
of mitochondrial protein synthesis, either low amounts of 
unassembled subunits a and A6L are still present, or that 
subunits a and A6L are regenerated from pre-existing F, or 
F, F,, complexes. Reassembly of F, with F, has for instance 
been reported in Escherichia coli (E. coli) [28] and in 
reconstitution experiments with the bovine enzyme [26]. 
The partial assembly pathway of the ATP synthase 
complex in human cells that can be deduced from our 
experiments (Fig. 5), corresponds very well with data 
obtained for the assembly of complex V in E. coli and 
yeast [27-301. Several experiments in these organisms 
indicate that synthesis and assembly of F, and F, can 
occur independently. A functional F, domain is, for in- 
stance, synthesized and assembled when F, subunits are 
transformed with a multicopy plasmid to bacteria in which 
the genes for the endogenous ATP synthase are deleted 
[28]. A functional F, domain is likewise formed when the 
genes for F0 subunits are expressed on the plasmid [29]. 
Whether this independent assembly reflects the physio- 
logical situation or is an artifact due to the unphysiological 
multicopy situation of the genes, has been questioned. 
However, it has been shown that also the presence of 
single copies of F, genes integrated in the E. coli genome 
with their natural promotor, result in assembly of an F, 
domain 1301. The latter study also demonstrated that the 
presence of F, increases the relative amounts of subunits a 
and b and leads to an F, domain that shows more resem- 
blance to that of wild-type cells, suggesting that in a 
wild-type situation F,, assembly is facilitated by F, or F, 
subunits. In yeast [27] immunoprecipitation experiments 
with subunit specific antisera indicate that F, is assembled 
first, followed by the integration of subunit c, whereafter 
incorporation of the remaining subunits of F, complete the 
formation of complex V. The assembly pattern in yeast is 
therefore probably identical to that in human cells. 
The results and methods presented in this study can be 
used to investigate the effect of mitochondrial mutations 
on the assembly of the ATP synthase complex. For in- 
stance, accumulation of a 390 kDa and 460 kDa ATPase 
subcomplexes in tissues from a patient with a point muta- 
tion in the mitochondrial gene for subunit a was recently 
shown[l7]. These results resemble the data of the present 
study for cells in which mitochondrial protein synthesis 
was inhibited. Our data support therefore the conclusion 
that the decreased ATP synthase activity in the patients in 
question is at least partially due to a decreased assembly of 
the ATP synthase complex [ 171. Metabolic labeling experi- 
ments and 2-D electrophoresis of mitochondrial enzymes 
in cultured cells, however, are necessary to provide more 
insight into how ATP synthase assembly is hampered in 
these patients. Studies into the assembly of ATP synthase 
in cultured cells from patients with mutations in one ore 
more of the ATP synthase subunits can likewise give more 
insight into the pathogenicity of these mutations and in the 
assembly pattern of human ATP synthase. 
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